private:miradx
|
858279
|
May 30th, 2019 12:00AM
|
MiraDx, Inc.
|
88
|
5.00
|
Open
|
Biotechnology
|
May 29th, 2019 08:36PM
|
May 29th, 2019 08:36PM
|
Mira Dx was co-founded by Joanne Weidhaas, M.D., Ph.D. and Frank Slack, Ph.D., whose cutting-edge genetic research has unveiled a new class of genetic biomarkers, based on microRNA biology. Our mission is to apply these novel biomarkers to dramatically improve personalized therapy.
Our biomarkers are germ-line, and disrupt microRNA target sites. We have been applying these biomarkers to better direct cancer treatments, including radiation, chemotherapy, and newly developing immune therapies. We are able to apply our biomarkers to the daunting problem of toxicity from treatment, which no other set of biomarkers has been able to do.
Through worldwide collaborations MiraDx has advanced this class of biomarkers to the forefront of personalized therapy, and has numerous collaborations across both academic and industry. We encourage you to learn more by visiting our website at MiraDx.com, as well as through visiting our sister non-profit, MiraKind, at MiraKind.org.
|
Open
|
|
Open
|
11600 Wilshire Blvd
|
Los Angeles
|
CA
|
US
|
90025
|
|
Mira Dx
|
|
Pharmaceuticals & Biotechnology
|
private:miradx
|
858279
|
Mar 18th, 2018 12:00AM
|
MiraDx, Inc.
|
65
|
5.00
|
Open
|
Biotechnology
|
Mar 18th, 2018 03:31PM
|
Mar 18th, 2018 03:31PM
|
|
Open
|
|
|
|
|
|
|
|
|
Mira Dx
|
|
Pharmaceuticals & Biotechnology
|
private:miradx
|
858279
|
Feb 17th, 2018 12:00AM
|
MiraDx, Inc.
|
58
|
6.00
|
Open
|
Biotechnology
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
Mira Dx was co-founded by Joanne Weidhaas, M.D., Ph.D. and Frank Slack, Ph.D., whose cutting-edge genetic research has unveiled a new class of genetic biomarkers, based on microRNA biology. Our mission is to apply these novel biomarkers to dramatically improve personalized therapy.
Our biomarkers are germ-line, and disrupt microRNA target sites. We have been applying these biomarkers to better direct cancer treatments, including radiation, chemotherapy, and newly developing immune therapies. We are able to apply our biomarkers to the daunting problem of toxicity from treatment, which no other set of biomarkers has been able to do.
Through worldwide collaborations MiraDx has advanced this class of biomarkers to the forefront of personalized therapy, and has numerous collaborations across both academic and industry. We encourage you to learn more by visiting our website at MiraDx.com, as well as through visiting our sister non-profit, MiraKind, at MiraKind.org.
|
|
|
|
|
|
|
|
|
|
Mira Dx
|
|
Pharmaceuticals & Biotechnology
|
private:miradx
|
858279
|
Feb 16th, 2018 12:00AM
|
MiraDx, Inc.
|
58
|
6.00
|
Open
|
Biotechnology
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
Mira Dx was co-founded by Joanne Weidhaas, M.D., Ph.D. and Frank Slack, Ph.D., whose cutting-edge genetic research has unveiled a new class of genetic biomarkers, based on microRNA biology. Our mission is to apply these novel biomarkers to dramatically improve personalized therapy.
Our biomarkers are germ-line, and disrupt microRNA target sites. We have been applying these biomarkers to better direct cancer treatments, including radiation, chemotherapy, and newly developing immune therapies. We are able to apply our biomarkers to the daunting problem of toxicity from treatment, which no other set of biomarkers has been able to do.
Through worldwide collaborations MiraDx has advanced this class of biomarkers to the forefront of personalized therapy, and has numerous collaborations across both academic and industry. We encourage you to learn more by visiting our website at MiraDx.com, as well as through visiting our sister non-profit, MiraKind, at MiraKind.org.
|
|
|
|
|
|
|
|
|
|
Mira Dx
|
|
Pharmaceuticals & Biotechnology
|
private:miradx
|
858279
|
Feb 15th, 2018 12:00AM
|
MiraDx, Inc.
|
58
|
6.00
|
Open
|
Biotechnology
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
Mira Dx was co-founded by Joanne Weidhaas, M.D., Ph.D. and Frank Slack, Ph.D., whose cutting-edge genetic research has unveiled a new class of genetic biomarkers, based on microRNA biology. Our mission is to apply these novel biomarkers to dramatically improve personalized therapy.
Our biomarkers are germ-line, and disrupt microRNA target sites. We have been applying these biomarkers to better direct cancer treatments, including radiation, chemotherapy, and newly developing immune therapies. We are able to apply our biomarkers to the daunting problem of toxicity from treatment, which no other set of biomarkers has been able to do.
Through worldwide collaborations MiraDx has advanced this class of biomarkers to the forefront of personalized therapy, and has numerous collaborations across both academic and industry. We encourage you to learn more by visiting our website at MiraDx.com, as well as through visiting our sister non-profit, MiraKind, at MiraKind.org.
|
|
|
|
|
|
|
|
|
|
Mira Dx
|
|
Pharmaceuticals & Biotechnology
|
private:miradx
|
858279
|
Feb 14th, 2018 12:00AM
|
MiraDx, Inc.
|
58
|
6.00
|
Open
|
Biotechnology
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
Mira Dx was co-founded by Joanne Weidhaas, M.D., Ph.D. and Frank Slack, Ph.D., whose cutting-edge genetic research has unveiled a new class of genetic biomarkers, based on microRNA biology. Our mission is to apply these novel biomarkers to dramatically improve personalized therapy.
Our biomarkers are germ-line, and disrupt microRNA target sites. We have been applying these biomarkers to better direct cancer treatments, including radiation, chemotherapy, and newly developing immune therapies. We are able to apply our biomarkers to the daunting problem of toxicity from treatment, which no other set of biomarkers has been able to do.
Through worldwide collaborations MiraDx has advanced this class of biomarkers to the forefront of personalized therapy, and has numerous collaborations across both academic and industry. We encourage you to learn more by visiting our website at MiraDx.com, as well as through visiting our sister non-profit, MiraKind, at MiraKind.org.
|
|
|
|
|
|
|
|
|
|
Mira Dx
|
|
Pharmaceuticals & Biotechnology
|
private:miradx
|
858279
|
Feb 13th, 2018 12:00AM
|
MiraDx, Inc.
|
58
|
6.00
|
Open
|
Biotechnology
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
Mira Dx was co-founded by Joanne Weidhaas, M.D., Ph.D. and Frank Slack, Ph.D., whose cutting-edge genetic research has unveiled a new class of genetic biomarkers, based on microRNA biology. Our mission is to apply these novel biomarkers to dramatically improve personalized therapy.
Our biomarkers are germ-line, and disrupt microRNA target sites. We have been applying these biomarkers to better direct cancer treatments, including radiation, chemotherapy, and newly developing immune therapies. We are able to apply our biomarkers to the daunting problem of toxicity from treatment, which no other set of biomarkers has been able to do.
Through worldwide collaborations MiraDx has advanced this class of biomarkers to the forefront of personalized therapy, and has numerous collaborations across both academic and industry. We encourage you to learn more by visiting our website at MiraDx.com, as well as through visiting our sister non-profit, MiraKind, at MiraKind.org.
|
|
|
|
|
|
|
|
|
|
Mira Dx
|
|
Pharmaceuticals & Biotechnology
|
private:miradx
|
858279
|
Feb 12th, 2018 12:00AM
|
MiraDx, Inc.
|
58
|
6.00
|
Open
|
Biotechnology
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
Mira Dx was co-founded by Joanne Weidhaas, M.D., Ph.D. and Frank Slack, Ph.D., whose cutting-edge genetic research has unveiled a new class of genetic biomarkers, based on microRNA biology. Our mission is to apply these novel biomarkers to dramatically improve personalized therapy.
Our biomarkers are germ-line, and disrupt microRNA target sites. We have been applying these biomarkers to better direct cancer treatments, including radiation, chemotherapy, and newly developing immune therapies. We are able to apply our biomarkers to the daunting problem of toxicity from treatment, which no other set of biomarkers has been able to do.
Through worldwide collaborations MiraDx has advanced this class of biomarkers to the forefront of personalized therapy, and has numerous collaborations across both academic and industry. We encourage you to learn more by visiting our website at MiraDx.com, as well as through visiting our sister non-profit, MiraKind, at MiraKind.org.
|
|
|
|
|
|
|
|
|
|
Mira Dx
|
|
Pharmaceuticals & Biotechnology
|
private:miradx
|
858279
|
Feb 11th, 2018 12:00AM
|
MiraDx, Inc.
|
58
|
6.00
|
Open
|
Biotechnology
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
Mira Dx was co-founded by Joanne Weidhaas, M.D., Ph.D. and Frank Slack, Ph.D., whose cutting-edge genetic research has unveiled a new class of genetic biomarkers, based on microRNA biology. Our mission is to apply these novel biomarkers to dramatically improve personalized therapy.
Our biomarkers are germ-line, and disrupt microRNA target sites. We have been applying these biomarkers to better direct cancer treatments, including radiation, chemotherapy, and newly developing immune therapies. We are able to apply our biomarkers to the daunting problem of toxicity from treatment, which no other set of biomarkers has been able to do.
Through worldwide collaborations MiraDx has advanced this class of biomarkers to the forefront of personalized therapy, and has numerous collaborations across both academic and industry. We encourage you to learn more by visiting our website at MiraDx.com, as well as through visiting our sister non-profit, MiraKind, at MiraKind.org.
|
|
|
|
|
|
|
|
|
|
Mira Dx
|
|
Pharmaceuticals & Biotechnology
|
private:miradx
|
858279
|
Feb 10th, 2018 12:00AM
|
MiraDx, Inc.
|
58
|
6.00
|
Open
|
Biotechnology
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
Mira Dx was co-founded by Joanne Weidhaas, M.D., Ph.D. and Frank Slack, Ph.D., whose cutting-edge genetic research has unveiled a new class of genetic biomarkers, based on microRNA biology. Our mission is to apply these novel biomarkers to dramatically improve personalized therapy.
Our biomarkers are germ-line, and disrupt microRNA target sites. We have been applying these biomarkers to better direct cancer treatments, including radiation, chemotherapy, and newly developing immune therapies. We are able to apply our biomarkers to the daunting problem of toxicity from treatment, which no other set of biomarkers has been able to do.
Through worldwide collaborations MiraDx has advanced this class of biomarkers to the forefront of personalized therapy, and has numerous collaborations across both academic and industry. We encourage you to learn more by visiting our website at MiraDx.com, as well as through visiting our sister non-profit, MiraKind, at MiraKind.org.
|
|
|
|
|
|
|
|
|
|
Mira Dx
|
|
Pharmaceuticals & Biotechnology
|